Sanjay Popat1, Anders Mellemgaard2, Martin Reck3, Claudia Hastedt4, Ingolf Griebsch4. 1. Department of Medicine (Lung), Royal Marsden Hospital, London, UK. 2. Department of Oncology, Herlev University Hospital, Copenhagen, Denmark. 3. Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany. 4. Boehringer Ingelheim GmbH, Ingelheim, Germany.
Abstract
PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1.20 [95% credible interval: 0.92-1.58]; PFS: HR: 0.91 [0.68-1.21]). Exploratory subgroup analysis indicated superiority of nivolumab in high PD-L1 expression level subgroups; results were more favorable for nintedanib in all subgroups with low (<1%, <5%, <10%) PD-L1 expression levels - in particular, with regard to PFS. CONCLUSION: Results demonstrated similar efficacy of nintedanib + docetaxel compared with the new therapeutic options ramucirumab + docetaxel and nivolumab, with potential differences in subgroups according to PD-L1 expression level.
PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1.20 [95% credible interval: 0.92-1.58]; PFS: HR: 0.91 [0.68-1.21]). Exploratory subgroup analysis indicated superiority of nivolumab in high PD-L1 expression level subgroups; results were more favorable for nintedanib in all subgroups with low (<1%, <5%, <10%) PD-L1 expression levels - in particular, with regard to PFS. CONCLUSION: Results demonstrated similar efficacy of nintedanib + docetaxel compared with the new therapeutic options ramucirumab + docetaxel and nivolumab, with potential differences in subgroups according to PD-L1 expression level.
Authors: Oscar Arrieta; Feliciano Barrón; Laura Alejandra Ramírez-Tirado; Zyanya Lucia Zatarain-Barrón; Andrés F Cardona; Diego Díaz-García; Masao Yamamoto Ramos; Beatriz Mota-Vega; Amir Carmona; Marco Polo Peralta Álvarez; Yolanda Bautista; Fernando Aldaco; Raquel Gerson; Christian Rolfo; Rafael Rosell Journal: JAMA Oncol Date: 2020-06-01 Impact factor: 31.777
Authors: Jeronimo Rafael Rodríguez-Cid; Saul Campos-Gomez; Vanessa García-Montes; Manuel Magallanes-Maciel; Rodrigo Rafael Flores-Mariñelarena; Valeria Michelle Fernández-Garibay; Iván Romarico González-Espinoza; Juan Paulo Ceja-García; Juan Carlos Cázarez-Price; Luis Martínez-Barrera; Leopoldo Barriguete-Parra; Carlos Jose Zuloaga-Fernandez; Roberto Kuri-Exsome; David Suárez-García; Jorge Ignacio Gonzalez-Villanueva; Noé Flores-Anaya; Jose Antonio Acevedo-Delgado; Alma Magdalena Astorga-Ramos; Raquel Gerson-Cwilich; Alberto Villalobos-Prieto; Claudia Rodríguez-Silva; Maria Fernanda Noriega-Iriondo; Leticia Vázquez-Cortés; Eusebio Perales-Rodríguez; Alicia Acosta-Espinoza; Yareni Perez-Lozano; Daniel Capdeville-García; Jorge Arturo Alatorre-Alexander Journal: JCO Glob Oncol Date: 2020-03